Baseline Distribution of Participants with Depression and Impaired Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial

Authors

Carine Hamo
John Heitner
Marc Pfeffer
Hae-Young Kim, New York Medical CollegeFollow
Christopher Kenwood
Susan AssmannFollow
Scott Solomon
Robin Boineau
Jerome Fleg
John Spertus
Eldrin Lewis

Additional Author Affiliation

New York Medical College

Author ORCID Identifier

http://orcid.org/0000-0001-7916-6625

DOI

10.1161/CIRCHEARTFAILURE.114.001838

Journal Title

Circulation: Heart Failure

First Page

268

Last Page

277

Document Type

Article

Publication Date

3-1-2015

Department

Public Health

Abstract

BACKGROUND: Previous studies have demonstrated the psychosocial effect of heart failure in patients with reduced ejection fraction. However, the effects on patients with preserved ejection fraction have not yet been elucidated. This study aimed to determine the baseline characteristics of participants with heart failure with preserved ejection fraction as it relates to impaired quality of life (QOL) and depression, identify predictors of poor QOL and depression, and determine the correlation between QOL and depression.

METHODS AND RESULTS: Among patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients completed the Kansas City Cardiomyopathy Questionnaire, 3395 patients completed European QOL 5D Visual Analog Scale, and 1431 patients in United States and Canada completed the Patient Health Questionnaire-9. The mean summary score on the Kansas City Cardiomyopathy Questionnaire was 54.8, and on European QOL 5D Visual Analog Scale, it was 60.3; 27% of patients had moderate to severe depression. Factors associated with better Kansas City Cardiomyopathy Questionnaire and European QOL 5D Visual Analog Scale via multiple logistic regression analysis were American region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and lower New York Heart Association class. Factors associated with depression via multiple logistic regression analysis included younger age, female sex, comorbid angina, chronic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher New York Heart Association class, and selective serotonin reuptake inhibitor use. There were significant correlations between each of the QOL scores and depression.

CONCLUSIONS: Patients with heart failure with preserved ejection fraction, who were younger had higher New York Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eastern Europe or were taking hypoglycemic agents, were more likely to have impaired QOL and depression.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.

Comments

At the time of publication, Dr. Kim was affiliated with New England Research Institutes in Watertown, MA.

Recommended Citation

Hamo C.E., Heitner J.F., Pfeffer M.A., Kim H.-Y., Kenwood C., Assmann S.F., Solomon S.D., Boineau R., Fleg J.L., Spertus J.A., Lewis E.F. Baseline Distribution of Participants with Depression and Impaired Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation: Heart Failure, 8(2); 268-77, (2015).